참고문헌
- 신정우 박능화. 만성 B형 간염의 치료. 대한내과학회지 77(3):265-274, 2009.
- Lok, A.S., McMahon, B.J. Chronic hepatitis B: update 2009. Hepatology. 50(3):661-662, 2009. https://doi.org/10.1002/hep.23190
- Chang, T.T., Gish, R.G., de Man, R., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 354(10):1001-1010, 2006. https://doi.org/10.1056/NEJMoa051285
- Tenney, D.J., Rose, R.E., Baldick, C.J., et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 49(5):1503-1514, 2009. https://doi.org/10.1002/hep.22841
- Zhang, L., Wang, G., Hou, W., Li, P., Dulin, A., Bonkovsky, H.L. Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review. Hepatology. 51(2):690-698, 2010. https://doi.org/10.1002/hep.23384
- 채우석. 동씨기혈집성. 서울, 일중사, pp 251-255, 1997.
- 전국 한의과대학 간계내과학교수 공저. 간계내과학 4판. 서울, 동양의학연구원, pp 256-290, 2001.
- European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 50(2):227-242, 2009. https://doi.org/10.1016/j.jhep.2008.10.001
- Dienstag, J.L., Schiff, E.R., Wright, T.L., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. New Engl J Med. 341(17):1256-1263, 1999. https://doi.org/10.1056/NEJM199910213411702
- Lai, C., Chien, R., Leung, N., et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 339(2):61-68, 1998. https://doi.org/10.1056/NEJM199807093390201
- Schalm, S.W., Heathcote, J., Cianciara, J., et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut. 46(4):562-568, 2000. https://doi.org/10.1136/gut.46.4.562
- Chang, T.T., Lai, C.L., Chien, R.N., et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol. 19(11):1276-1282, 2004. https://doi.org/10.1111/j.1440-1746.2004.03428.x
- Lok, A.S., Lai, C.L., Leung, N., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 125(6):1714-1722, 2003. https://doi.org/10.1053/j.gastro.2003.09.033
- Hadziyannis, S., Tassopoulos, N., Heathcote, E., et al. Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years. Gastroenterology. 131(6):1743-1751, 2006. https://doi.org/10.1053/j.gastro.2006.09.020
- Marcellin, P., Heathcote, E.J., Buti, M., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 359(23):2442-2455, 2008. https://doi.org/10.1056/NEJMoa0802878
- Chang, T.T., Gish, R.G., de Man, R., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 354(10):1001-1010, 2006. https://doi.org/10.1056/NEJMoa051285
- Lai, C.L., Shouval, D., Lok, A.S., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 354(10):1011-1020, 2006. https://doi.org/10.1056/NEJMoa051287
- Sherman, M., Martin, P., Lee, W., et al. Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026). Gastroenterology. 130(Suppl 2):A765, 2006.
- Tenney, D.J., Rose, R.E., Baldick, C.J., et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49(5):1503-1514, 2009. https://doi.org/10.1002/hep.22841
- Lai, C.L., Gane, E., Liaw, Y.F., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 357(25):2576-2588, 2007. https://doi.org/10.1056/NEJMoa066422
- Lim, S.G., Ng, T.M., Kung, N., et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med. 166(1):49-56, 2006. https://doi.org/10.1001/archinte.166.1.49
- Yoo, B.C., Kim, J.H., Chung, Y.H., et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology. 45(5):1172-1178, 2007. https://doi.org/10.1002/hep.21629
- Ferrucci, L.M., Bell, B.P., Dhotre, K.B., Manos, M.M., Terrault, N.A., Zaman, A., Murphy, R.C., Vanness, G.R., Thomas, A.R., Bialek, S.R., Desai, M.M., Sofair, A.N. Complementary and alternative medicine use in chronic liver disease patients. J Clin Gastroenterol. 44(2):e40-45, 2010. https://doi.org/10.1097/MCG.0b013e3181b766ed